Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

70 Applying Pharmacogenomics in Therapeutics
63. Donzelli E, Carfi M, Miloso M, et al. Neurotoxicity of platinum compounds:
Comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell
line SH-SY5Y. Journal of Neuro-Oncology 2004;67:65–73.
64. Sakano S, Hinoda Y, Sasaki M, et al. Nucleotide excision repair gene polymorphisms
may predict acute toxicity in patients treated with chemoradiotherapy for bladder
cancer. Pharmacogenomics 2010;11:1377–87.
65. Caronia D, Patino-Garcia A, Milne RL, et al. Common variations in ERCC2 are associated
with response to cisplatin chemotherapy and clinical outcome in osteosarcoma
patients. The Pharmacogenomics Journal 2009;9:347–53.
66. D’Arcangelo M, Cappuzzo F. Erlotinib in the first-line treatment of non-small-cell lung
cancer. Expert Review of Anticancer Therapy 2013;13:523–33.
67. Cho SH, Park LC, Ji JH, et al. Efficacy of EGFR tyrosine kinase inhibitors for nonadenocarcinoma
NSCLC patients with EGFR mutation. Cancer Chemotherapy and
Pharmacology 2012;70:315–20.
68. Han SW, Kim TY, Lee KH, et al. Clinical predictors versus epidermal growth factor
receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer
(Amsterdam, Netherlands) 2006;54:201–7.
69. Scheinfeld N. Three cases of toxic skin eruptions associated with methotrexate and a compilation
of methotrexate-induced skin eruptions. Dermatology Online Journal 2006;12:15.
70. Guaiana G, Barbui C, Hotopf M. Amitriptyline for depression. The Cochrane Database
of Systematic Reviews 2007;3:CD004186.
71. Estebe JP, Myers RR. Amitriptyline neurotoxicity: Dose-related pathology after topical
application to rat sciatic nerve. Anesthesiology 2004;100:1519–25.
72. Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive
disorder. The Cochrane Database of Systematic Reviews 2012;12:CD009138.
73. Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question:
Pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high
risk for side effects in amitriptyline therapy. Clinical chemistry 2005;51:376–85.
74. Koski A, Sistonen J, Ojanpera I, Gergov M, Vuori E, Sajantila A. CYP2D6 and
CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal
autopsies. Forensic Science International 2006;158:177–83.
75. Shimoda K, Someya T, Yokono A, et al. The impact of CYP2C19 and CYP2D6
genotypes on metabolism of amitriptyline in Japanese psychiatric patients. Journal of
Clinical Psychopharmacology 2002;22:371–8.
76. de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and
metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized
patients. The Pharmacogenomics Journal 2011;11:359–67.
77. Kwadijk-de Gijsel S, Bijl MJ, Visser LE, et al. Variation in the CYP2D6 gene is associated
with a lower serum sodium concentration in patients on antidepressants. British
Journal of Clinical Pharmacology 2009;68:221–5.
78. Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on
dose, switching and discontinuation of antidepressants. British Journal of Clinical
Pharmacology 2008;65:558–64.
79. Ravna AW, Sylte I, Dahl SG. Molecular mechanism of citalopram and cocaine
interactions with neurotransmitter transporters. The Journal of Pharmacology and
Experimental Therapeutics 2003;307:34–41.
80. Schmidt HM, Hagen M, Kriston L, Soares-Weiser K, Maayan N, Berner MM.
Management of sexual dysfunction due to antipsychotic drug therapy. The Cochrane
Database of Systematic Reviews 2012;11:CD003546.
81. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant
treatment in the STAR*D cohort. The American Journal of Psychiatry
2007;164:1181–8.